Oncostatin m receptor antigen binding proteins
AssigneeKiniksa Pharmaceuticals, GmbH
InventorsHeather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
Life of this patent
Estimating the term…
Abstract
The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
Claims43
1-74. (canceled)
A method of treating pruritis, said method comprising administering a therapeutically effective amount of an anti-oncostatin M receptor (OSMR) antibody to a patient in need thereof.
A method of treating a disease or disorder associated with OSMR-mediated signaling, said method comprising administering a therapeutically effective amount of an anti-oncostatin M receptor (OSMR) antibody comprising:
- a) a light chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29;
- or
- b) a heavy chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:53, or SEQ ID NO:
- 54.
A method of treating a disease or disorder associated with OSMR-mediated signaling, said method comprising administering a therapeutically effective amount of an anti-oncostatin M receptor (OSMR) antibody, comprising:
- a) a light chain variable domain comprising a light chain complementary-determining region 1 (LCDR1) having at least 90% identity to SEQ ID NO:31, a light chain complementary-determining region 2 (LCDR2) having at least 90% identity to SEQ ID NO:34, and a light chain complementary-determining region 3 (LCDR3) having at least 90% identity to SEQ ID NO:37;
- and
- b) a heavy chain variable domain comprising a heavy chain complementary-determining region 1 (HCDR1) having at least 90% identity to SEQ ID NO:13, a heavy chain complementary-determining region 2 (HCDR2) having at least 90% identity to SEQ ID NO:
- 16, and a heavy chain complementary-determining region 3 (HCDR3) having at least 90% identity to SEQ ID NO:19.
A method of treating a disease or disorder associated with OSMR-mediated signaling, said method comprising administering a therapeutically effective amount of an anti-oncostatin M receptor (OSMR) antibody comprising:
- a) a light chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29;
- and
- b) a heavy chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:53, or SEQ ID NO:
- 54.
An anti-OSMR antibody that competes with an antibody comprising a) a light chain variable domain having the amino acid sequence set forth in SEQ ID NO:28;
- and b) a heavy chain variable domain having the amino acid sequence set forth in SEQ ID NO:54.
An anti-OSMR antibody that competes with an antibody comprising
- a light chain variable domain comprising a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO:31, a light chain complementary-determining region 2 (LCDR2) defined by SEQ ID NO:34, and a light chain complementary-determining region 3 (LCDR3) defined by SEQ ID NO:37;
- and
- a heavy chain variable domain comprising a heavy chain complementary-determining region 1 (HCDR1) defined by SEQ ID NO:
- 13, a heavy chain complementary-determining region 2 (HCDR2) defined by SEQ ID NO:
- 16, and a heavy chain complementary-determining region 3 (HCDR3) defined by SEQ ID NO:19.
An anti-OSMR antibody comprising
- a) a light chain variable domain comprising a light chain complementary-determining region 1 (LCDR1) having at least 90% identity to SEQ ID NO:31, a light chain complementary-determining region 2 (LCDR2) having at least 90% identity to SEQ ID NO:34, and a light chain complementary-determining region 3 (LCDR3) having at least 90% identity to SEQ ID NO:37;
- and
- b) a heavy chain variable domain comprising a heavy chain complementary-determining region 1 (HCDR1) having at least 90% identity to SEQ ID NO:13, a heavy chain complementary-determining region 2 (HCDR2) having at least 90% identity to SEQ ID NO:
- 16, and a heavy chain complementary-determining region 3 (HCDR3) having at least 90% identity to SEQ ID NO:19.
Dependencies are inferred from the claim text.